sunitinib + sorafenib + pazopanib

This is a combination of three small molecule tyrosine kinase inhibitors—sunitinib, sorafenib, and pazopanib. Each drug individually targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR). Sunitinib inhibits VEGFR-1/2/3, PDGFR-α/β, c-KIT, FLT3, RET; sorafenib inhibits VEGFR-2/3, PDGFR-β, RAF kinases; pazopanib inhibits VEGFR-1/2/3, PDGFR-α/β, c-KIT. All three are approved for the treatment of advanced renal cell carcinoma and have been studied as monotherapies or in sequential regimens but not as a triple combination due to overlapping toxicities. Their mechanisms involve blocking angiogenesis and tumor proliferation pathways[1][6][7]. There is no evidence that this specific triple combination is used clinically or has been formally studied as a single regimen.